High1/2 relationships sourcedProfile verified Aug 13, 2026
OverviewMore SignalsSourcesM&A fitRelationship mapStoryMilestones

30-Second Executive Brief

Executive Assessment

Neko Health functions as an established institution within Healthcare & Life Sciences, backed by 55% sourcing coverage, with accelerating strategic relevance.

  • Maintains 2 mapped relationships across the graph
  • 55% sourcing coverage across sourced relationships
  • Tracked as established institution within the Healthcare & Life Sciences category

Executive Snapshot

Strategic Role
Established Institution
Sourcing Coverage
55%
View Methodology →

Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.

Ecosystem Influence
High
Strategic Momentum
Accelerating

Coverage

Mapped Relationships
2
Technology Domains
5

Strategic Implications

  • Central node connecting multiple strategic ecosystems
  • Directly influences technology and capital flows
  • Material relevance to downstream dependency mapping

Top Opportunities

International clinic expansion beyond its current Nordic/European base$700M Series C proceeds are earmarked specifically for launching clinics in New York and other major US cities, marking Neko's first major push into the world's largest healthcare market

Top Risks

High-volume scanning model requires continued capital to scale physical clinic locationsNearly $7B valuation on a pre-revenue-scale US expansion plan creates significant markdown risk if clinic rollout or demand falls short of expectations

Critical Dependencies

Continue to Dependency Graph ↓

A Swedish preventive-health company co-founded by former Spotify CEO Daniel Ek, offering full-body scans using roughly 70 sensors for mole mapping and other diagnostics, paired with an AI-powered health-prediction tool. Neko has raised over $1B cumulatively and carries a 100,000+ person waitlist — a direct global comparison point for Lifecore's diagnostics and AI-concierge offering.

⚡

Additional Intelligence Signals

Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.

⚡

Sources

Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.

Evidence

2 sources

  • CB Insights — Neko Health profiled among leading longevity/preventive-health startupsresearch
  • Axios — Neko Health raises $700M at $7B valuationnews

Correlated Activity

Both Neko Health and Lifecore — which it depends on — are showing accelerating Activity at the same time (1 recorded change for Lifecore in the last 90 days).

Timing correlation only — not evidence of a causal link

⚡

Acquisition & Investment Fit

AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.

⚡

Relationship Map

The relationships surrounding Neko Health — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.

2 levels3 levels 🔒5 levels 🔒

Connection type

Sign in free to click a node and explore →

Click any node to make it the new center. Scroll to zoom, drag to pan.

⚡

The Story So Far (last 6 months)

Jul 2026: Raises $700M Series C at ~$7B valuation→Jul 2026: Neko Health raises $700M at $7B valuation→Aug 2026: Neko Health's ~$7B valuation sets the highest disclosed benchmark among global preventive… (unconfirmed)

Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.

Market Intelligence

Unverified

Credibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.

Neko Health's ~$7B valuation sets the highest disclosed benchmark among global preventive-diagnostics peers

40% confidence

At nearly $7 billion, Neko Health's post-Series C valuation is now well above disclosed valuations for comparable preventive-diagnostics platforms such as Prenuvo (~$600M) and the smaller-funded Human Longevity and Fountain Life, suggesting investors are pricing full-body-scan platforms with celebrity/consumer-brand pull and rapid US expansion plans at a substantial premium over more clinically incremental peers.

This cross-company valuation comparison is InsightNodes' own synthesis of separately reported, differently-dated valuation figures (Neko's July 2026 raise vs. Prenuvo's February 2025 raise); valuations at different points in time and market conditions are not perfectly comparable, so this should be read as a directional benchmark rather than a precise like-for-like comparison.

InsightNodes analysis of Axios and CB Insights reporting · Aug 13, 2026

PrenuvoHuman Longevity, Inc.Fountain LifeLifecore
⚡

Neko Health's Timeline

A sourced, dated history of Neko Health's key moments — founding to present.

  1. Jul 2026 · Raises $700M Series C at ~$7B valuation

    Neko Health raised a $700 million Series C round led by Lightspeed Venture Partners and O.G. Venture Partners at a valuation of nearly $7 billion — a fourfold jump from its $1.7 billion Series B in January 2025 — with investors including Mark Zuckerberg, Priscilla Chan, Tim Ferriss, and OpenAI, to fund US clinic expansion into New York and other cities.